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Abstract Therapeutic vaccination with dendritic cells
(DC) is an emerging investigational therapy for eradication
of minimal residual disease in acute myeloid leukemia.
Various strategies are being explored in manufacturing DC
vaccines ex vivo, e.g., monocyte-derived DC (MoDC)
loaded with leukemia-associated antigens (LAA). How-
ever, the optimal source of LAA and the choice of DC-
activating stimuli are still not well deﬁned. Here, loading
with leukemic cell preparations (harboring both unknown
and known LAA) was explored in combination with a DC
maturation-inducing cytokine cocktail (CC; IL-1b, IL-6,
TNF-a, and PGE2) and Toll-like receptor ligands (TLR-L)
to optimize uptake. Since heat shock induced apoptotic
blasts were more efﬁciently taken up than lysates, we
focused on uptake of apoptotic leukemic cells. Uptake of
apoptotic blast was further enhanced by the TLR7/8-L
R848 (20–30%); in contrast, CC-induced maturation
inhibited uptake. CC, and to a lesser extent R848, enhanced
the ability of MoDC to migrate and stimulate T cells.
Furthermore, class II-associated invariant chain peptide
expression was down-modulated after R848- or CC-
induced maturation, indicating enhanced processing and
presentation of antigenic peptides. To improve both uptake
and maturation, leukemic cells and MoDC were co-incu-
bated with R848 for 24 h followed by addition of CC.
However, this approach interfered with CC-mediated
MoDC maturation as indicated by diminished migratory
and T cell stimulatory capacity, and the absence of IL-12
production. Taken together, our data demonstrate that even
though R848 improved uptake of apoptotic leukemic cells,
the sequential use of R848 and CC is counter-indicated due
to its adverse effects on MoDC maturation.
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Introduction
Acute myeloid leukemia (AML) is characterized by the
proliferation of clonal neoplastic myeloid hematopoietic
precursor cells and impaired normal hematopoiesis.
Although 70–80% of patients (\60 years) achieve com-
plete remission after intensive chemotherapy, AML fre-
quently relapses due to the persistence of minimal residual
disease (MRD) [1]. Escape of leukemic cells from immune
surveillance has been associated with the poor clinical
outcome. For instance, a high occupancy of HLA-DR
molecules with the class II-associated invariant chain
peptide (CLIP) instead of an antigenic peptide is correlated
with a shortened disease-free and overall survival [2, 3].
In contrast, immune control of leukemia, as shown for
instance by the graft-versus-leukemia effect induced
by allogeneic stem cell transplantation (SCT) or the rein-
duction of complete remission after donor lymphocyte
infusion following allogeneic SCT, demonstrates the
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AML therapy [1].
The induction, regulation, and maintenance of primary
immune responses, including speciﬁc anti-tumor T cell
responses are coordinated by dendritic cells (DC). Vacci-
nation with DC has been recognized as a promising
investigational therapy due to the uniquely powerful anti-
gen (Ag)-presenting capacity of DC and its potential to
circumvent immunosuppressive features of leukemia [4].
The ﬁrst steps down the road to DC vaccination in AML
have been taken and results from small clinical trials have
been reported [5]. The general lack of clinical responses
evoked important questions concerning the optimal meth-
odologies for DC vaccine preparation as well as the design
of clinical vaccination protocols. Many strategies are
explored in the preparation of DC vaccines ex vivo; among
these, autologous monocyte-derived DC (MoDC) loaded
with leukemia-associated Ag (LAA) are promising [6].
Various sources of LAA and different methods of loading
LAA onto DC have been explored in an attempt to opti-
mize anti-tumor responses [7]. For AML, several relevant
LAA have been identiﬁed including PRAME, RHAMM,
WT1, and PR1. Unfortunately, overexpression of these
LAA is common, but not uniform in leukemia [8]. More-
over, HLA restriction of LAA-derived peptides limits
application of such vaccines to patients with certain HLA
proﬁles. These restrictions inherent to the use of deﬁned
LAA or LAA-derived peptides may be overcome using the
whole AML cells as a source of LAA, for instance by
generation of AML lysates or apoptotic leukemic cells.
Among other whole AML cell-derived antigen loading
strategies that have been explored is electroporation of DC
with AML-derived RNA [9]. Also vaccination with mod-
iﬁed AML cells, such as AML-derived DC or fusions
between AML cells and DC, has been investigated; further
modiﬁcation of DC with 4-1BB-L or CD40 might enhance
the efﬁcacy of such vaccines [10–13]. It has long been
assumed that the apoptotic cell death is poorly immuno-
genic or even tolerogenic, whereas necrotic cell death is
considered to be immunogenic. However, stress-induced
heat shock protein (HSP)-peptide complexes (commonly
induced during apoptosis) are more efﬁciently taken up via
scavenger receptors and Toll-like receptors (TLR) on the
DC surface and induce efﬁcient cross-priming and skewing
of the immune response towards a Th1-type proﬁle [14,
15], whereas necrosis has been associated with the local
immune suppression in solid tumors [16]. Furthermore,
apoptosis induction after irradiation with UV light or by
treatment with chemotherapeutic drugs results in upregu-
lation of calreticulin, a scavenger receptor class-A ligand
associated with immunogenic apoptosis as demonstrated
for colon carcinoma cells [17, 18]. For AML, it is not yet
clear whether cell lysates or apoptotic cells are preferable
for Ag loading onto MoDC [9, 19–25]. Next to enhancing
immunogenicity of tumor Ag sources by, for instance,
heat shock, addition of DC-maturing stimuli, such as Toll-
like receptor ligands (TLR-L), is explored; e.g., electro-
poration of TLR3-L Poly(I:C) into AML cells results in
enhanced uptake of leukemic cells by DC and improves
their subsequent maturation and cytokine production [26].
Furthermore, intracellular binding of TLR8 by its ligand
R848 has been reported to result in enhanced cross-
priming of exogenous Ag by MoDC [27]. Various whole
AML cell preparations loaded onto MoDC in combination
with DC maturation-inducing cocktails have been
explored [9, 21]; however, the quantitative effects of
TLR-L and cytokines on uptake of leukemic cells are still
unclear.
In this study, we compared the uptake of allogeneic
apoptotic leukemic cells with lysates derived from leukemic
cells. We investigated the uptake of heat shock-induced
apoptotic leukemic cells by MoDC and DC maturation
by combining a standard cytokine cocktail (CC) with the
clinically applicable TLR7/8-L R848.
Materials and methods
Patient samples
Peripheral blood or bone marrow mononuclear cells from
AML patients were isolated by density centrifugation using
Ficoll-Paque (Amersham Pharmacia Biotech, Uppsala,
Sweden). All samples were drawn after obtaining the
patients’ informed consent at the time of collection. Cells
were cultured immediately or cryopreserved at a controlled
rate in liquid nitrogen using RPMI-1640 medium (Gibco,
Paisley, UK) supplemented with 20% heat-inactivated FCS
(Greiner, Alphen a/d Rijn, The Netherlands) and 10%
dimethylsulphoxide (Merck, Darmstadt, Germany). Before
application of stored AML cells, cryopreserved material
was rapidly thawed and washed twice in RPMI-1640 sup-
plemented with 40% FCS. The cells were then resuspended
in culture medium as described below.
Culture of monocyte-derived dendritic cells
Buffy coats wereobtained fromhealthy volunteers according
to the institutional guidelines. Peripheral blood mononuclear
cells (PBMC) were isolated by density centrifugation using
Ficoll-Paque. Subsequently, monocytes were obtained by
magnetic bead isolation, using CD14-labeled microbeads
(Miltenyi Biotec GmbH, Bergisch Gladbach, Germany).
MoDC were cultured from CD14
? monocytes in CellGro
serum-free medium (CG) (CellGenix, Freiburg, Germany)
supplemented with 100 IU/ml penicillin and 100 lg/ml
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123streptomycin, GM-CSF (800 IU/ml, speciﬁc activity
1 9 10
5 IU/mg protein; Pepro Tech, Rocky Hill, NJ), and
IL-4 (500 IU/ml, speciﬁc activity 1 9 10
7 IU/mg protein,
PeproTech).After5 days,immatureMoDCwereharvested.
Purity and phenotype of immature DC were evaluated by
ﬂow cytometry for the expression of CD14, CD40, CD34,
CD80, CD86, HLA-DR, CD54, and CD83. For maturation
induction, the following TLR-L were used: R848 (3 lg/ml;
Alexis Biochemicals, Axxora, Gru ¨nberg, Germany), LPS
(100 ng/ml; Sigma-Aldrich, Saint Louis, MO), polyino-
sinic–polycyticylic acid potassium salt (Poly(I:C); 25 lg/ml;
Sigma-Aldrich), ﬂagellin (5 lg/ml; Invivogen, San Diego,
CA), and peptidoglycan (PGN; 5 lg/ml; Sigma-Aldrich).
Maturation with CC was induced using the following com-
bination of cytokines and reagents: recombinant TNF-a
(200 IU/ml; Strathmann Biotec, Hannover, Germany),
IL-1b (10 ng/ml; Strathmann Biotec), PGE2 (1 lg/ml;
Sigma-Aldrich), and IL-6 (10 ng/ml; R&D Systems,
Abingdon, UK).
Loading of MoDC with allogeneic leukemic cell lysates
and apoptotic leukemic cells
Leukemic cells were labeled with 5- (and 6-) carboxy-
ﬂuorescein diacetate, succinimidyl ester (CFSE; Molecular
Probes, Eugene, Oregon). Cells were suspended in buffered
saline (PBS) at 10 9 10
6-1 ml and labeled for 10 min with
1 M CFSE at 37C, washed three times with RPMI-1640,
10% FCS and incubated overnight in RPMI-1640, sup-
plemented with 100 IU/ml penicillin and 100 lg/ml
streptomycin and 10% FCS. Leukemic cells were harvested
and taken up in PBS and apoptosis was induced by heat
shock (2 h at 42C) or by incubation for 2 h at 37C with
ARA-C (10 lg/ml; Mayne Pharma, Warwickshire, UK).
The percentage of necrotic, apoptotic, and viable cells was
determined before and after apoptosis induction by incu-
bation with Syto-62 (5 nM; Molecular Probes, Eugene,
OR), PSC833 (2 lM; Novartis, Basel, Switzerland) and
7-aminoactinomycin D (7-AAD; ViaProbe, Pharmingen,
San Diego, CA) for 45 min at 37C, and by ﬂow cytometric
analysis as described previously [28]. Syto-62 is a ﬂuo-
rescent nucleic acid stain that exhibits bright ﬂuorescence
upon binding to nucleic acids and is retained in viable cells.
Together with the dead-cell dye 7-aminoactinomycin D
(7-AAD), discrimination between viable (Syto?/7AAD-)
and early (Syto-/7AAD-) and late (Syto-/7AAD?) stages
of apoptosis can be made. MoDC were labeled with CellVue
Plum (Polysciences, Washington, CO) or with PKH26
(Sigma, Missouri, USA) according to the manufacturers’
guidelines. After labeling, DC were washed three times
and put in CG medium. MoDC were cultured in a 1:1
or 1:3 ratio with pretreated leukemic cells in CG medium
combined with 100 IU/ml penicillin and 100 lg/ml
streptomycin and 800 IU/ml GM-CSF and 500 IU/ml
IL-4 at 37C, 5% CO2. Using different time schedules,
cultures were supplemented with the indicated maturation
stimuli.
Flow cytometric analysis of MoDC
Four-color ﬂow cytometry was performed on a FACS-
Calibur ﬂow cytometer (Becton Dickinson, San Jose, CA).
Results were analyzed using CellQuest software (Becton
Dickinson). Immature DC and DC after maturation were
stained by appropriate dilutions or mouse isotype-matched
control mAb of ﬂuorescein isothiocyanate (FITC)-labeled
CD14 (Becton Dickinson, San Jose, CA), CD1a (Sanquin),
CD54 (DAKO, Glostrup, Denmark). Phyco-erythrin (PE)-
labeled monoclonal antibodies (mAb) were used against
CD40 (Coulter Immunotech, Marseilles, France), CD80,
CD86, CCR-7 (CD197, Becton Dickinson, San Jose, CA),
CLIP (cerCLIP.1; Santa Cruz Biotechnology, Santa Cruz
CA), CD83 (Coulter Immunotech) and peridinin chloro-
phyll protein (PerCP)-labeled anti-HLA-DR and CD34
(Becton Dickinson). Isotype controls used were FITC-
labeled IgG1 (DAKO) and IgG2b (Sanquin), PE-labeled
IgG1 (Becton Dickinson) and IgG2b (DAKO), and PerCP-
labeled IgG1 and IgG2a (Becton Dickinson). For HLA-
DO and HLA-DM, the following mouse mAb were used:
HLA-DM (Becton Dickinson) and IgG1 isotype control
(Becton Dickinson); FITC-labeled HLA-DO (Becton
Dickinson) and IgG2b (Becton Dickinson). Cells were
stained for DO and DM after ﬁxation with paraformal-
dehyde followed by permeabilization with PBS–0.1%
Saponine (Sigma-Aldrich). Results are presented as either
the percentage of positive cells compared to the appro-
priate isotype control or the mean ﬂuorescence index
(MFI). MFI represents the mean ﬂuorescence obtained
through binding of the mAb of interest divided by the
mean ﬂuorescence of the appropriate isotype control.
Relative CLIP expression was determined by calculating
the ratio between CLIP and HLA-DR expression based on
both the percentage and MFI of positive cells, as descri-
bed previously [2].
DC migration assay
The migratory capacity of DC was evaluated in a transwell
system (5 lm poresize, Corning Costar, Corning, NY,
USA) under serum-free conditions. Cells were allowed to
migrate 16 h towards medium with or without chemo-
attractant CCL19 (MIP3b, 300 ng/ml; R&D Systems,
Abingdon, UK). The percentage of migrated cells was
quantiﬁed by ﬂow cytometry using a ﬁxed amount of
ﬂuorescent beads as a reference (FlowCount Fluorospheres,
Coulter, Miami, FL, USA).
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DC were harvested, washed, and seeded in a 96-well
round-bottomed plate at 40 9 10
3 cells in 200 llo f
medium containing 10% FCS per well. CD40L-expressing
cells (i.e., muCD154-transfected J558 cells) were used as
stimulator cells at 40 9 10
3 per well. After 24 h, super-
natants were harvested and analyzed for IL-12 by ELISA,
as described previously [29].
Mixed leukocyte reaction
The ability of the various AML-loaded DC to stimulate T
cells was tested in an allogeneic mixed leukocyte reaction
(MLR). After isolation of PBMC from a buffy-coat, CD8
?
cells were obtained by magnetic cell sorting with anti-
CD8-labeled magnetic microbeads (Miltenyi Biotec
GmbH, Bergisch Gladbach, Germany) and used as
responder cells. DC were irradiated at 30 Gy and then
added to round-bottomed 96-well tissue-culture plates
(Costar, Corning, NY) at various stimulator to responder
ratios. All ratios were tested in triplicate; cells were cul-
tured in RPMI containing 10% FCS. After 5 days, thymi-
dine was added (0.4 lCi per well; Amersham Pharmacia
Biotech, Buckinghamshire, UK) for 16 h, after which the
cells were harvested onto ﬁberglass ﬁlters and
3H-thymi-
dine incorporation was determined using a ﬂatbed scintil-
lation counter (Wallac, Turku, Finland).
Statistical analysis
Statistical signiﬁcance of differences between the various
loading and maturation procedures was determined by the
paired sample Student’s t test (two-tailed). P values of
\0.05 were regarded as signiﬁcant.
Results
Uptake of apoptotic leukemic cells or lysates by MoDC
is a dose-dependent and active process
To investigate the use of whole leukemic cells as a source
of LAA for loading onto DC, we co-incubated MoDC from
healthy donors (HD) with either apoptotic leukemic cells or
lysates, each labeled with different ﬂuorochromes. Apop-
totic samples contained less than 25% (range 25–0%)
viable cells; the ratio of early apoptotic/viable cells was
ﬁve times higher after 2 h incubation at 42C compared
with the control situation (2 h at 37C, data not shown).
The percentages of apoptotic cells did not differ between
the methods [incubation with Cytarabine (ARA-C) or heat
shock (HS) at 42C] used to induce apoptosis. Uptake of
apoptotic cells or apoptotic cell fragments and lysates by
MoDC was dose-dependent (Fig. 1a). Moreover, uptake of
HS-induced apoptotic AML cells was more efﬁcient than
AML lysates (p = 0.03; paired t test, n = 6; tested in
MoDC from three different HD). Fluorescence microscopic
observations revealed actual uptake of AML preparations
and not mere binding to DC cell surface (Fig. 1b). Co-
incubation of CFSE-labeled leukemic cells with MoDC for
2 h at 37C resulted in high levels of CFSE
? MoDC
(35%), whereas co-incubation for 2 h at 0C resulted in
only low percentages of CFSE
? MoDC (5%), indicating
that the observed uptake is an active endocytic process
(Fig. 1c, d). The efﬁciency of uptake differed per patient;
no correlation was observed regarding AML subtype or
percentage of apoptotic cells. Since HS-induced apoptotic
leukemic cells were more efﬁciently taken up than lysates,
further analysis was focused on uptake of HS-induced
apoptotic leukemic cells.
Uptake of heat shock-induced apoptotic AML cells
by MoDC is enhanced by R848 and diminished
by a DC maturation-inducing cytokine cocktail
As TLR-mediated activation of DC has previously been
associated with enhanced endocytosis [30], we tested the
inﬂuence of the clinically applicable TLR-L Poly(I:C), and
R848 and, as well as PGN, ﬂagellin and LPS on AML cell
uptake by MoDC. Administration of a maturation-inducing
CC 2 h after co-incubation of MoDC with lysed or apop-
totic leukemic cells resulted in a signiﬁcantly lower uptake
by MoDC (Fig. 2). Of all the TLR-L tested (data of
Poly(I:C), R848, LPS, PGN, and ﬂagellin not shown), only
R848 was able to enhance the uptake of HS-induced
apoptotic leukemic cells signiﬁcantly. Of note, addition of
R848 enhanced uptake of apoptotic but not of lysed AML
cells by MoDC (Fig. 2). Remarkably, combined adminis-
tration of R848 and CC abolished this positive effect. We
hypothesized that the prolonged incubation with R848
combined with delayed administration of CC might result
in higher uptake. Therefore, we pre-incubated HS-induced
apoptotic leukemic cells and MoDC with R848 for 24 h,
after which CC was added for 48 h (Fig. 3). In this time
frame, we found more efﬁcient uptake of HS-induced
apoptotic leukemic cells by R848-treated MoDC as com-
pared to control and CC-treated MoDC. However, this
enhanced uptake was counteracted by sequential incuba-
tion with CC.
Maturation induction of AML-loaded MoDC
Next, we investigated if incubation of MoDC from HD
with AML cells with or without R848 and/or CC affected
their maturation state. Uptake of HS-induced apoptotic
40 Cancer Immunol Immunother (2011) 60:37–47
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CD86 and CD40 expression (Fig. 4). Addition of CC 24 h
after loading resulted in MoDC maturation as shown by de
novo expression of CD83 and chemokine receptor CCR7
(Fig. 4). Only partial maturation was induced after addition
of R848 alone, as demonstrated by low-level CD83
expression and the absence of CCR7. Of note, pre-incu-
bation with R848 blocked full maturation by CC as shown
by signiﬁcantly lower levels of CD83, CCR7, CD40, and
CD86 (Fig. 4).
MHC class II antigen presentation requires the exchange
of CLIP for an antigenic peptide in the peptide-binding
groove, a process that is catalyzed by HLA-DM. HLA-DO,
another nonclassical MHC class II molecule, is able to
down-regulate the catalytic function of HLA-DM [2]. The
intensity of HLA-DR varied between the different matu-
ration stimuli (data not shown). Relative to HLA-DR,
moderate CLIP down-regulation was observed upon load-
ing of immature DC with HS-induced apoptotic AML cells,
but a more profound decrease in CLIP expression was seen
upon maturation induction by R848 and/or CC (Fig. 4e).
These data indicate efﬁcient HLA-DR-mediated presenta-
tion of endocytosed antigens after maturation. Both HLA-
DM and -DO levels were in accordance with the observed
relative CLIP levels (data not shown).
Function of heat shock-induced apoptotic AML-loaded
versus unloaded MoDC
To further investigate the effects of the applied loading
strategies on HD-derived MoDC, we examined their
migratory and T cell stimulating capacity. Upon CC-
induced maturation, the lymph node homing receptor
CCR7 was upregulated (Fig. 4b). In line with this, matu-
ration with CC resulted in a high migration rate towards the
CCR7 ligand CCL19; combined maturation with R848
resulted in lower migration efﬁciencies (Fig. 5a).
In response to overnight CD40 ligation, HS-induced
apoptotic AML-loaded MoDC stimulated with R848 or
CC released reduced levels of the Th1-skewing and
Fig. 1 Uptake of leukemic cells by MoDC is a dose-dependent and
active process. Leukemic cells were labeled with CFSE and
subsequently apoptosis was induced by heat shock at 42Co r
incubation with ARA-C for 2 h; lysates were generated by three
freeze-thawing cycles. Immature MoDC were labeled with CellVue
Plum (emitting in the FL4 channel) or with PKH-26 (emitting in the
FL2 channel) and co-incubated with leukemic cells. a Uptake of
leukemic cells by MoDC is depicted after 24 h of co-incubation.
Results of 1:3 leukemic cell:DC ratio (ﬁlled bars) are presented as
relative uptake compared to uptake at leukemic cell:DC ratio of 1:1
(open bars)( n = 14 ± SEM). b CFSE-positive MoDC after co-
incubation of CFSE labeled lysate (9400). Dot plots representing
uptake of CFSE-labeled leukemic cells after 2 h incubation at 0C
(c)o r3 7 C( d); insets represent percentage of PKH26-labeled MoDC
positive for CFSE
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stimulated unloaded MoDC [mean relative decrease
(±SD): 0.65 (±0.27) and 0.52 (±0.16), respectively;
median IL12 production unloaded non-stimulated MoDC:
520 (286–5199) pg/ml] (Fig. 5b). Of note, IL-12p70
release was almost completely abolished by the combined
sequential use of R848 and CC [mean relative decrease
0.97 (±0.06)]. However, incubation with R848 and CC
increased the ability of MoDC to prime naı ¨ve T cells in an
allogeneic MLR in accordance with the observations for
Fig. 2 Differential effects of
R848 and a cytokine cocktail on
uptakeofapoptoticAMLcellsor
AMLlysates.ApoptosisofAML
cells was induced by heat shock
at 42C or incubation in ARA-C
for 2 h. Leukemic cells and
MoDC were incubated for 2 h,
R848 was added for another 2 h
for the R848 and R848 and
cytokine cocktail (CC)
conditions. Four hours after the
startofco-culture,CCwasadded
for the CC and R848 and CC
condition (as depicted in the
schematic illustration). Uptake
was measured by ﬂow cytometry
and indicated as the percentage
of CFSE-positive MoDC, 48 h
after the start of co-culture.
Relative uptake of leukemic cell
products by MoDC is depicted,
i.e., relative increase as
compared to no addition of
cytokines or R848. Mean
percentage ofCFSE-positive DC
in the control group is listed in
the lower left corner of each
graph; horizontal lines represent
means, *p\0.05; n = 6
Fig. 3 Differential effects of R848 and a cytokine cocktail on uptake
of apoptotic AML. Uptake of leukemic cell preparations by MoDC is
depicted. Apoptosis of AML cells was induced by heat shock for 2 h
at 42C. After 24 h of co-incubation of apoptotic leukemic cells and
MoDC, either in presence or absence of R848, a cytokine cocktail
(CC) was added. Uptake was measured by ﬂow cytometry and
indicated as the percentage of CFSE-positive MoDC, 72 h after the
start of co-culture. Relative increase to no addition of cytokines or
R848 is depicted. Mean percentage of CFSE-positive MoDC from the
control group is listed in the lower left corner of the graph; horizontal
lines represent means, *p\0.05; **p\0.005, n = 5
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incubation with R848 enhanced T cell stimulating capacity,
but not to the same level as seen for CC alone (Fig. 5c).
Discussion
This study was undertaken to investigate the various
MoDC vaccine preparation strategies in order to create an
optimized MoDC vaccine for the treatment of MRD in
AML. The ability of HD-derived MoDC to take up whole
cell-derived material in combination with TLR-L was
investigated in order to enhance the uptake of LAA. Fur-
thermore, we explored the capability of MoDC to mature
under the inﬂuence of various TLR-L and a standard CC as
positive control.
Immature DC are capable of taking up Ag, e.g., from
infected cells or tumor cells, in the form of apoptotic
bodies or necrotic cell particles [31, 32]. Next to the Ag
source, agents such as TLR-L or cytokines can affect the
outcome of this uptake [33]. Upon encounter with for
instance microbial agents or other inﬂammatory stimuli,
DC mature from cells specialized in Ag uptake into cells
specialized in T cell stimulation. Inﬂammatory cytokines
are considered as strong maturation inducers but, as we
demonstrated, CC inhibits further Ag uptake by DC. In
contrast, TLR-L are known to enhance the uptake of
antigenic material and subsequently induce maturation
[30]. In accordance with this, we found the enhanced
uptake after co-incubation with TLR- L R848, whereas
addition of CC after 24 h of co-incubation with R848
halted further uptake.
Fig. 4 Immunophenotype of
MoDC after co-incubation with
apoptotic leukemic cells.
Marker expression levels of
a CD83, b CCR7, c CD86,
d CD40, and e relative CLIP are
shown after uptake of heat
shock-induced apoptotic
leukemic cells by MoDC, either
in presence or absence of R848
or CC; the time intervals used
are depicted in the schematic
illustration in f. For CD83 and
CCR7, the percentage of
positive cells is shown (a, b,
respectively). For CD86 and
CD40, mean ﬂuorescence
indices (MFI, as calculated in
relation to the isotype control)
are shown (c, d, respectively)
(n = 10). Fold change
compared with immature
MoDC (immat) in relative CLIP
expression is depicted in e by
calculating the ratio of CLIP
and HLA-DR expression as
indicated in ‘‘Material and
methods’’ (n = 13). Horizontal
lines represent mean, *p\0.05,
**p\0.005
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inﬂuenced the amount of cellular material taken up by
MoDC: less uptake was achieved in DC after co-incubation
with lysate as compared to apoptotic cells. In the process of
dying, apoptotic cells are known to shed immunogenic
particles, i.e., so-called blebs. Murine studies have dem-
onstrated that these blebs are taken up more efﬁciently by
DC than the remaining, larger, apoptotic bodies [34]. This
may offer an explanation for our observation that the
apoptotic AML cells are more efﬁciently taken up by
MoDC than AML lysates. Additional knowledge about the
ability of DC to prime LAA-speciﬁc T cells is clearly
warranted to further differentiate between both whole
leukemic cell-derived antigen sources.
One of the key players in the MHC class II presentation
pathway is CLIP and its regulators HLA-DM and HLA-
DO. TLR-L regulate processing of the invariant chain (Ii)
and inﬂuence the exchange of CLIP with antigenic pep-
tides. TLR signaling is necessary to direct the internalized
antigens via the classical pathway for presentation by MHC
II, whereas tolerogenic DC can upregulate CLIP expression
and hamper T cell signaling [35–37]. Consistent with this,
CLIP expression was decreased when DC and apoptotic
AML cells were co-incubated in the presence of R848 and/
or CC, indicative of a putative increase in LAA presenta-
tion by the loaded MoDC.
Maturation of DC is necessary to enable migration to
lymph nodes and activation of T cells. Consistent with
Fig. 5 Function of unloaded
and heat shock-induced
apoptotic leukemic cell loaded
MoDC after incubation with or
without R848 and/or cytokine
cocktail. a Migration of DC
towards CCL19 was tested in a
0.5-lm pore transwell system;
percentages of MoDC that
migrated towards CCL19 (gray
bars) and medium (white bars)
are depicted; *p\0.05. b IL-
12p70 production was measured
after overnight CD40 ligation;
relative IL-12p70 release
compared with immature
unloaded MoDC is depicted,
mean IL-12p70 release in the
control group is listed in the
lower left corner of the graph;
*p\0.05; **p\0.005. c The
ability of DC to induce
proliferation in a mixed
leukocyte reaction is shown
after 5 days of co-incubation of
MoDC and allogeneic CD8
? T
cells in various MoDC:T cell
ratios. [
3H]thymidine was added
and incorporation was measured
after 16 h. Each ratio was tested
in triplicate and means ± SD
are shown. One representative
experiment out of six is shown
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123literature, CC induced upregulation of CD86, expression of
CD83, CCR7, and hence enhanced migratory capacity, the
latter most likely due to the presence of prostaglandin-E2
(PGE2) in the cocktail. R848 is able to induce phenotypic
maturation, but far less prominently than CC [38, 39]. In
this setting, our results indicate that R848 is rather an
enhancer of antigen uptake than a straightforward matu-
ration inducer, whereas CC only promotes maturation. We
hypothesized that both high uptake and maturation might
be achieved by combining prolonged R848 incubation
(24 h) followed by the addition of CC. However, matura-
tion was only slightly increased compared to R848 alone.
These data indicate that TLR-L antagonize the maturation
efﬁcacy of CC. Recent studies showed the inhibitory
effects of TLR-L LPS and Poly(I:C) on DC by the acti-
vation of so-called suppressors of cytokine signaling
(SOCS). It has been described that SOCS1, 2, and 3 are
required for appropriate TLR signaling in maturing human
DC via both the MyD88-dependent and -independent sig-
naling pathway [40–43]. By ﬁrst enhancing uptake with
TLR-L, the DC might become resistant to cytokines due to
the activation of SOCS1/2, resulting in disturbed matura-
tion. Moreover, TLR-mediated induction of maturation-
inhibitory cytokines (e.g., IL-10) might be responsible for
this maturation inhibitory effect [44, 45]. We did the
attempt inhibition of putatively involved down-stream
signaling elements (a.o. p38 MAPK, PI3 K, STAT3) to
abolish this R848-mediated block in CC-induced DC
maturation, but to no avail.
PGE2, part of the cytokine cocktail, is known to impair
production of IL-12p70 [46, 47]. As a consequence of
reduced IL-12p70 levels, immunosuppressive cells, such as
T regulatory cells might be recruited [48, 49]. Various
combinations of cytokines and other DC-maturing factors,
such as TLR-L, direct MoDC maturation towards a
migratory and/or Th1-activating cytokine release proﬁle
[38, 50]. Recently, it was shown that the simultaneous
addition of PGE2 and TLR 3/7/8 ligands resulted in higher
levels of co-stimulatory molecules on DC as well as IL-
12p70 production and migration capacity [38, 51]. We
hypothesized that by pre-incubating MoDC with R848,
followed by maturation with CC (containing PGE2), both
effective IL-12p70 production, migratory capacity as well
as improved AML cell uptake might be established.
Addition of CC after prolonged incubation with R848
enhanced the migratory capacity, but not to the same levels
as CC alone. Furthermore, IL-12p70 production was
abolished as compared to CC stimulation alone. This might
be explained by the longer incubation time and, thereby
exhaustion of MoDC before measuring the overnight IL-
12p70 production. However, in a mixed leukocyte reaction,
we demonstrated that the CD8
? T cell stimulatory capacity
of R848 and/or CC matured MoDC was signiﬁcantly
higher than that of controls, indicating that irrespective of
IL-12p70 production, R848 and/or CC matured DC is able
to stimulate CD8
? T cells. Since IL-12p70 is an important
cytokine in Th1 and CTL activation, careful analysis of the
ability to prime functional leukemia-speciﬁc T cells is
needed to design optimal MoDC vaccine preparation
strategies.
In conclusion, our results demonstrate that the uptake of
leukemic cells by MoDC and their maturation state is
differentially affected by TLR-L R848 and CC. As com-
pared to CC alone, the sequential use of R848 and CC
interfered with the effective MoDC maturation as indicated
by diminished migration and T cell stimulatory capacity,
and abolished IL-12p70 production. These ﬁndings do not
justify incorporation of TLR7/8-L in DC-maturing cock-
tails for clinical development of whole-cell AML-loaded
MoDC vaccines.
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